CVS Picks Amgen's Repatha Over Sanofi-Regeneron's Cholesterol Drug
Nov 23 U.S. drug benefit manager CVS Health said on Monday that it would add Amgen Inc.'s Repatha cholesterol treatment to its list of covered drugs for private plans over a competing treatment from Sanofi SA and Regeneron Pharmaceuticals.
The two competing treatments, which can slash "bad" LDL cholesterol by more than 60 percent, were approved this summer by the U.S. Food and Drug Administration and belong to a new class of medicines called PCSK9 inhibitors.
Their pricetags have drawn criticism at a time when the national focus has turned to increases in costs of healthcare, and in particular, drugs for consumers.
The two competing treatments, which can slash "bad" LDL cholesterol by more than 60 percent, were approved this summer by the U.S. Food and Drug Administration and belong to a new class of medicines called PCSK9 inhibitors.
Their pricetags have drawn criticism at a time when the national focus has turned to increases in costs of healthcare, and in particular, drugs for consumers.